A statement on vemurafenib-resistant melanoma

Journal of Investigative Dermatology

Volumn 133, Issue 8, 2013, Pages 1928-1929

  Hartsough, Edward J ^a   Aplin, Andrew E ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; FIBROBLAST GROWTH FACTOR 2; HEAT SHOCK PROTEIN 90 INHIBITOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR PAX3; UNCLASSIFIED DRUG; VEMURAFENIB; WP1066;

CANCER INHIBITION; CANCER RESISTANCE; FIBROBLAST; HEAD AND NECK TUMOR; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; LYMPHOMA; MELANOMA; MELANOMA CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84880372025     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.136     Document Type: Note

References (8)

1. Aplin AE, Kaplan FM, Shao Y (2011) Mechanisms of resistance to RAF inhibitors in melanoma. J Invest Dermatol 131:1817-20
2. Dong L, Li Y, Cao J et al. (2012) FGF2 regulates melanocytes viability through the STAT3-transactivated PAX3 transcription. Cell Death Diff 19:616-22
3. Kong LY, Abou-Ghazal MK, Wei J et al. (2008) A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res 14:5759-68
4. Krasilnikov M, Ivanov VN, Dong J et al. (2003) ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene 22:4092-101 (Pubitemid 36819649)
5. Liu F, Cao J, Wu J et al. (2013) Stat3 targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Invest Dermatol 133:2041-9
6. Mascarenhas JB, Littlejohn EL, Wolsky RJ et al. (2010) PAX3 and SOX10 activate MET receptor expression in melanoma. Pigment Cell Melanoma Res 23:225-37
7. Paraiso KH, Haarberg HE, Wood E et al. (2012) The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res 18:2502-14
8. Straussman R, Morikawa T, Shee K et al. (2012) Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500-4